Vaxart Inc (VXRT)
0.9446
+0.08
(+9.24%)
USD |
NASDAQ |
May 15, 16:00
0.97
+0.03
(+2.69%)
After-Hours: 20:00
Vaxart Free Cash Flow: -67.95M for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
Date | Value |
---|---|
March 31, 2024 | -67.95M |
December 31, 2023 | -72.32M |
September 30, 2023 | -86.92M |
June 30, 2023 | -93.32M |
March 31, 2023 | -103.62M |
December 31, 2022 | -104.38M |
September 30, 2022 | -93.19M |
June 30, 2022 | -87.10M |
March 31, 2022 | -74.24M |
December 31, 2021 | -64.99M |
September 30, 2021 | -59.83M |
June 30, 2021 | -53.80M |
March 31, 2021 | -38.97M |
December 31, 2020 | -24.97M |
September 30, 2020 | -17.11M |
June 30, 2020 | -12.00M |
March 31, 2020 | -11.95M |
December 31, 2019 | -13.94M |
September 30, 2019 | -16.03M |
June 30, 2019 | -17.11M |
March 31, 2019 | -9.73M |
December 31, 2018 | -15.26M |
September 30, 2018 | -14.06M |
June 30, 2018 | -13.03M |
March 31, 2018 | -18.73M |
Date | Value |
---|---|
December 31, 2017 | -19.50M |
September 30, 2017 | -23.80M |
June 30, 2017 | -30.00M |
March 31, 2017 | -30.20M |
December 31, 2016 | -25.80M |
September 30, 2016 | -25.90M |
June 30, 2016 | -14.30M |
March 31, 2016 | -15.10M |
December 31, 2015 | -7.30M |
September 30, 2015 | 2.80M |
June 30, 2015 | -9.70M |
March 31, 2015 | 0.80M |
December 31, 2014 | 0.70M |
September 30, 2014 | -8.70M |
June 30, 2014 | -3.40M |
March 31, 2014 | -15.95M |
December 31, 2013 | -18.77M |
September 30, 2013 | -11.89M |
June 30, 2013 | |
March 31, 2013 | |
December 31, 2012 | |
September 30, 2012 | -6.293M |
June 30, 2012 | -9.875M |
March 31, 2012 | -8.079M |
December 31, 2011 | -15.17M |
Free Cash Flow Range, Past 5 Years
-104.38M
Minimum
Dec 2022
-11.95M
Maximum
Mar 2020
-55.69M
Average
-62.41M
Median
Free Cash Flow Benchmarks
Novavax Inc | -514.43M |
aTyr Pharma Inc | -58.00M |
Allogene Therapeutics Inc | -227.48M |
AIM ImmunoTech Inc | -21.85M |
Protalix BioTherapeutics Inc | 4.369M |
Free Cash Flow Related Metrics
Cash from Operations (Quarterly) | -21.19M |
Cash from Investing (Quarterly) | -5.024M |
Cash from Financing (Quarterly) | 18.20M |
Free Cash Flow Per Share (Quarterly) | -0.1263 |
Free Cash Flow to Equity (Quarterly) | -21.32M |
Free Cash Flow to Firm (Quarterly) | -21.02M |
Free Cash Flow Yield | -47.77% |